Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2017 · 10-Q
Revenue$0.00$0.00— vs Q2 2016 Net Income-$2.46M-$2.46MN/M vs Q2 2016 EPS Diluted$479,053.00$479,053.00+798,421,566.7% vs Q2 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flowderived-$391,000N/M Free Cash Flowderived-$391,000— ended Jun 30, 2017 · filed Aug 11, 2017 · 42 d after period end